Comparison between hepatic resection and radiofrequency ablation as first-line treatment for solitary small-sized hepatocellular carcinoma of 3 cm or less

2013 ◽  
Vol 43 (8) ◽  
pp. 853-864 ◽  
Author(s):  
Kastunori Imai ◽  
Toru Beppu ◽  
Akira Chikamoto ◽  
Koichi Doi ◽  
Hirohisa Okabe ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiofrequency Ablation ◽  
Hepatic Resection ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

scholarly journals Ten-year survival of hepatocellular carcinoma patients undergoing radiofrequency ablation as a first-line treatment

2016 ◽  
Vol 22 (10) ◽  
pp. 2993 ◽  
Author(s):  
Wei Yang ◽  
Kun Yan ◽  
S Nahum Goldberg ◽  
Muneeb Ahmed ◽  
Jung-Chieh Lee ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiofrequency Ablation ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

Stereotactic radiofrequency ablation as first-line treatment of recurrent HCC following hepatic resection

2020 ◽  
Vol 46 (8) ◽  
pp. 1503-1509
Author(s):  
Peter Schullian ◽  
Gregor Laimer ◽  
Daniel Putzer ◽  
Elliot Levy ◽  
Eva Braunwarth ◽  
...  
Keyword(s):  
Radiofrequency Ablation ◽  
Hepatic Resection ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

Survival of patients receiving radiofrequency ablation or ethanol injection for early-stage hepatocellular carcinoma.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e15043-e15043
Author(s):  
Zhong-Zhe Lin ◽  
Wen-Yi Shau ◽  
Yu Yun Shao ◽  
Yi-Chun Yeh ◽  
Raymond Nien-Chen Kuo ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiofrequency Ablation ◽  
Early Stage ◽  
Stage I ◽  
Claim Database ◽  
Line Treatment ◽  
First Line ◽  
Ethanol Injection ◽  
Co Morbidity ◽  
First Line Treatment

e15043 Background: Randomized trials suggest that radiofrequency ablation (RFA) may be more effective than percutaneous ethanol injection (PEI) in the treatment of hepatocellular carcinoma (HCC). However, the survival advantage of RFA need confirmation in daily practice. Methods: We conducted a population-based cohort study using the Taiwan Cancer Registry, National Health Insurance claim database and National Death Registry data from 2004 through 2009. Patients receiving PEI or RFA as first-line treatment for newly-diagnosed stage I-II HCC were enrolled. Results: A total of 658 patients receiving RFA and 378 patients receiving PEI treatment were included for final analysis. The overall survival (OS) rates of patients in the RFA and PEI groups at 5-year were 55% and 42%, respectively (p< 0.01). Compared to patients that received PEI, those that received RFA had lower risks of overall mortality and first-line treatment failure (FTF), with adjusted hazard ratios (HRs) [95% confidence interval (C.I.)] of 0.60 (0.50-0.73) for OS and 0.54 (0.46-0.64) for FTF. The favorable outcomes for the RFA group were consistently significant for patients with tumors > 2 cm as well as for those with tumors < 2 cm. Consistent results were also observed in other subgroup analyses defined by gender, age, tumor stage, and co-morbidity status. Conclusions: RFA provides better survival benefits than PEI for patients with unresectable stage I-II HCC, irrespective of tumors > 2 cm or ≤ 2 cm, in contemporary clinical practice.

Sign in / Sign up

Export Citation Format

Share Document